Yan Wang

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1K citations

Hepatology, Bevacizumab Biosimilar, Medicine +8

The Ecology, Genetic Diversity, and Phylogeny of Huaiyangshan Virus in China

Yong‐Zhen Zhang, Dun‐Jin Zhou, Xin-Cheng Qin et al. · Journal of Virology · 2011 · 233 citations · Full text

Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005–2010

Loren G. Miller, D. Eisenberg, Honghu Liu et al. · BMC Infectious Diseases · 2015 · 183 citations · Full text

The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients

Minghui Zhang, Yuandi Dong, Haitao Liu et al. · Scientific Reports · 2016 · 147 citations · Full text

Activation of Nrf2 pathway and inhibition of NLRP3 inflammasome activation contribute to the protective effect of chlorogenic acid on acute liver injury

Ameng Shi, Haitao Shi, Yan Wang et al. · International Immunopharmacology · 2017 · 130 citations

Immunology, Cell Death, Oxidative Stress +16